Topical QR-313 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene



Status:Recruiting
Conditions:Skin and Soft Tissue Infections, Skin and Soft Tissue Infections
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:6 - Any
Updated:2/22/2019
Start Date:July 2, 2018
End Date:April 17, 2019
Contact:Clinical Trial Manager
Email:clinical@proqr.com
Phone:+31881667000

Use our guide to learn which trials are right for you!

A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene

A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose
study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in
subjects with confirmed RDEB diagnosis with one or more pathogenic mutations in exon 73 in
the COL7A1 gene.

This clinical trial will evaluate the safety and tolerability, proof of mechanism, systemic
exposure and preliminary efficacy following topical application of QR-313 to subjects with
confirmed RDEB with one or more pathogenic mutations in exon 73 in the COL7A1 gene.

Up to two Target Wound Areas (TWAs) per subject will be selected and randomized. Each TWA
will be treated with IMP for 4 weeks, either QR-313 or matching placebo. All subjects will
continue to be followed up for 8 weeks post last dose.

Subjects will be monitored through home visits and site visits. An imaging system will be
used to assess the target wound at all home and study site visits.

QR-313 is a 21-nucleotide antisense oligonucleotide (AON) designed to hybridize to a specific
sequence in the COL7A1 pre-messengerRNA (pre-mRNA).

Inclusion Criteria:

1. Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of RDEB with
confirmation of at least one of the alleles of the COL7A1 gene containing one or more
pathogenic mutations in exon 73.

2. Have at least one TWA, ie, a skin area of 10 x 10 cm that shows no signs of local
infection, and contains a target wound that shows dynamic wound healing and complies
to the following additional criteria:

1. surface area of the target wound ranging from 5 to 60 cm2, located centrally in
the selected 10 x 10 cm TWA.

2. exposed sub-epidermal tissue to allow absorption of the IMP.

3. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.

Exclusion Criteria:

1. Pregnant or breast-feeding female

2. Hemoglobin level at Screening requiring transfusion. The subject may be rescreened
when the condition is considered stable.

3. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to
Screening, except adequately treated cutaneous squamous or basal cell carcinoma.

4. Life expectancy less than 6 months, as assessed by the Investigator

5. Current or known history of clinically significant hepatic or renal disease, that in
the opinion of the Investigator, could impact subject safety or study participation.

6. Treatment with any systemic immunomodulators, immunosuppressants or cytotoxic
chemotherapy within 2 months prior to the Baseline visit.

7. Use of any investigational drug or device within 28 days or 5 half-lives of the
Baseline visit, whichever is longer, or plans to participate in another study of a
drug or device during the study period. The washout of 5 half-lives does not apply to
gene and cell therapy.

8. Known hypersensitivity to oligonucleotide treatment or excipients of the IMP.
We found this trial at
5
sites
Cincinnati, Ohio 45229
Principal Investigator: Anne Lucky, MD
Phone: 513-803-9009
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Anna L Bruckner, MD
Phone: 720-777-4708
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Minneapolis, Minnesota 55454
Principal Investigator: Christen Ebens, MD
Phone: 612-626-8094
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Palo Alto, California 94305
Principal Investigator: Peter Marinkovich, MD
Phone: 650-721-4902
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
149 Rue de Sèvres
Paris, 75743
Principal Investigator: Christine Bodemer, Pr
Phone: +331 44 49 47 44
?
mi
from
Paris,
Click here to add this to my saved trials